Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead compound, GX15-070 (obatoclax), induced potent cytotoxic responses against patient-derived multiple myeloma tumor cells as a single-agent, and enhanced anti-myeloma effects when used as a combination therapy. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

"The ability of GX15-070 to inhibit tumor progression and also enhance the effects of other treatment modalities that often suffer from resistance is encouraging," stated Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "This study describes the novel activity of this compound and supports its therapeutic use in diverse cancer types, including multiple myeloma."

In the preclinical studies, GX15-070 potently inhibited the viability of 15 of 16 human myeloma cell lines (HMCLs), including those resistant to treatment with melphalan (a chemotherapeutic) and dexamethasone (a corticosteroid). Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome inhibitor. Additionally, single-agent studies of the candidate showed that it induced potent cytotoxic responses against patient-derived tumor cells without inducing cytotoxicity to human blood lymphocytes.

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1 trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. G
'"/>




Page: 1 2

Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/22/2014)... July 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... enrollment and dosing of patients in its ongoing Phase ... pancreatic cancer under the revised clinical protocol agreed to ... PEGylated form of Halozyme,s proprietary recombinant human hyaluronidase under ... hyaluronan. "Our diligent effort to rapidly ...
(Date:7/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... chief financial officer of the company, effective July 22, ... president and chief financial officer of Elan Corporation, a ... was part of a senior team that helped build ... to Perrigo, a pharmaceutical manufacturer, in December 2013. ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3ConvaTec Names Nigel Clerkin Chief Financial Officer 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... Women ages 65-69 who break a hip are five times more ... age who don,t break a hip, according to a Kaiser Permanente ... Health and published online today in the Archives of Internal ... by age group. In addition to the finding for women ages ...
... 26, 2011 UHC, an alliance of the nation,s ... a mobile analytics application for Spend LINK®, UHC,s ... subset of Spend LINK® reports that can be ... developed by Novation, UHC,s supply contracting company, allows users ...
Cached Medicine Technology:Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 2Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 3Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 4UHC Launches Analytics Mobile App to Help Members Improve Supply Chain Return on Investment 2UHC Launches Analytics Mobile App to Help Members Improve Supply Chain Return on Investment 3
(Date:7/22/2014)... Greensboro, NC (PRWEB) July 22, 2014 ... and faster for military veterans who have hands-on medical ... North Carolina at Greensboro today announced the launch of ... for military experience. , The new program, the UNCG ... a cohort of approximately 24 veterans. With some prior ...
(Date:7/22/2014)... Rosa Beach, FL (PRWEB) July 22, 2014 ... announce that they are now an authorized Daikin comfort ... offer and install Daikin indoor heating and cooling system ... and each one is thoroughly reviewed before being approved. ... is an innovator in the Split System Air Conditioning ...
(Date:7/22/2014)... Dr. Jeremy K. Ueno, of ... recently discussed the reasons for an increase in patients ... profession are seeing the amount of referrals they get ... one surgeon reported that over 50% of his implant ... have a very high success rate of up to ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's ... McPhearson, an insurance veteran with more than 15 years ... be based in the company's Chicago office. , UBA ... Les chose to accept this important, strategic position with ... many challenges facing UBA and its Partners as we ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 A Florida ... ) that alleges the death of her husband ... the blood thinner, Bernstein Liebhard LLP reports. According to ... District Court for the Southern District of Florida on ... 2012, and suffered a subdural hemorrhage the following June. ...
Breaking Medicine News(10 mins):Health News:UNCG School of Nursing Fast-Tracks Medically Trained Veterans 2Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3
... at Intermountain Medical Center in Salt Lake City believe ... fibrillation, a fairly common heart rhythm disorder, and Alzheimer,s ... In a study presented Friday, May 15, at "Heart ... Rhythm Society in Boston, researchers unveiled findings from the ...
... HAIKOU CITY, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ... specialty pharmaceutical products in China, today,announced financial results for the ... First Quarter 2009 Financial Highlights, -- ... the, first quarter of ...
... Prayerful Approach to Pain in Steinbach, Manitoba , ... Steinbach, Manitoba, Canada ... suffer in silence from chronic pain. Even pop singer, famed choreographer, and ... chronic pain in the May issue of Ladies Home Journal. While ...
... Brookdale Senior Living Inc. (NYSE: BKD ) today ... will make a presentation regarding the Company at the JMP ... 19, 2009, beginning at 2:30 p.m. Pacific Time.The presentation is ... Internet at , http://www.wsw.com/webcast/jmp8/bkd/ ...
... 14, 2009)A study of targeted educational initiatives between the ... hospitals within their Partners program suggest that educational interventions ... for cancer patients at community hospitals. The study, ... the American Society of Clinical Oncology, looked specifically at ...
... cancer patients , , THURSDAY, May 14 (HealthDay News) -- ... many grandmothers are already familiar with, and report that ... , "Ginger at a daily dose of 0.5-to-1 gram ... the first day of chemotherapy, and reduced nausea will ...
Cached Medicine News:Health News:Study makes first connection between heart disorder and Alzheimer's disease 2Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 2Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 3Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 4Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 5Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 6Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 7Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 8Health News:Chronic Pain Sufferers Find Hope in the Darkness 2Health News:Educational initiatives improve quality of care delivery 2Health News:Ginger Eases Nausea From Chemo 2
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
... The Guglielmi Detachable Coil is intended for: ... because of,their morphology, their location, or the ... by the treating,neurosurgical team to be a) ... operative techniques, or b) inoperable.,The GDC is ...
Care must be taken to operate the power unit slowly to help eliminate the possibility of breaking the wires by over-tightening....
Large solid mallet with patented Ortho-Grip® silicone rubber handle....
Medicine Products: